A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. [electronic resource]
Producer: 20150302Description: 762-8 p. digitalISSN:- 1573-0646
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Capecitabine
- Carcinoma, Hepatocellular -- drug therapy
- Deoxycytidine -- administration & dosage
- Female
- Fluorouracil -- administration & dosage
- Humans
- Interferon-alpha -- administration & dosage
- Liver Neoplasms -- drug therapy
- Male
- Middle Aged
- Niacinamide -- adverse effects
- Phenylurea Compounds -- adverse effects
- Polyethylene Glycols -- administration & dosage
- Recombinant Proteins -- administration & dosage
- Sorafenib
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.